ČESKÁ UROLOGIE / CZECH UROLOGY – 4 / 2018

250 Ces Urol 2018; 22(4): 242–250 PŘEHLEDOVÝ ČLÁNEK 18. Babjuk M, Koštířová M, Mudra K, et al. Místo neinvazivních testů (BTA STAT, BTA TRAK, UBC RAPID, UBC IRMA) a cytologie při sledování pacientů s povrchovými nádory močového měchýře. Ces Urol. 2001; 5(3): 9–13. 19. Szakácsová M, Soukup V, Babjuk M, et al. Exprese genů BCL-2 a BAX-1 ve tkáni Ta, T1 uroteliálních karcinomů močového měchýře a jejich prognostický význam. Ces Urol 2013; 17(3): 204–209. 20. Pešl M, Soukup V, Babjuk M, et al. Význam stanovení močové hladiny TATI (tumour associated trypsin inhibitor) pro diagnostiku a prognózu tumorů močového měchýře. Ces Urol. 2015; 19(1): 44–50. 21. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers ver‑ sus cytology: results of a comprehensive literature review and meta‑analyses. Urology 2003; 61(1): 109–18; discussion 18. 22. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 1998; 4(10): 2511–2520. 23. Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996; 156(2 Pt 1): 363–367. 24. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23(1): 18–20. 25. Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014; 65(2): 360–366. 26. Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect pa‑ tient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sciences U S A. 2013; 110(43): 17426–17431. 27. Ward DG, Baxter L, Gordon NS, et al. Multiplex PCR and next generation sequencing for the non‑invasive detection of bladder cancer. PloS one. 2016; 11(2): e0149756. 28. Pivovarcikova K, Pitra T, Vanecek T, et al. Comparative study of TERT gene mutation analysis on voided liquid‑based urine cytology and paraffin‑embedded tumorous tissue. Ann Diagn Pathol. 2016; 24: 7–10. 29. Ward DG, Bryan RT. Liquid biopsies for bladder cancer. Transl Androl Urol. 2017; 6(2): 331–335. 30. Birkenkamp‑Demtroder K, Christensen E, Nordentoft I, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol. 2017. 31. Pardini B, Cordero F, Naccarati A, et al. MicroRNA profiles in urine by next‑generation sequencing can stratify bladder cancer subtypes. Oncotarget. 2018; 9(29): 20658–20669. 32. Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non‑muscle‑invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017; 71(3): 447–461. 33. Roupret M, Babjuk M, Comperat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018; 73(1): 111–122. 34. Kamat AM, Hegarty PK, Gee JR, et al. ICUD‑EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013; 63(1): 4–15. 35. Tan WS, Sarpong R, Khetrapal P, et al. Does urinary cytology have a role in haematuria investigations? BJU Int. 2018 Jul 12. doi: 10.1111/bju.14459. [Epub ahead of print]. 36. Meilleroux J, Daniel G, Aziza J, et al. One year of experience using the Paris System for Reporting Urinary Cytology. Cancer Cytopathol. 2018; 126(6): 430–436. 37. Wang Y, Auger M, Kanber Y, Caglar D, Brimo F. Implementing The Paris System for Reporting Urinary Cytology results in a decrease in the rate of the „atypical“ category and an increase in its prediction of subsequent high‑grade urothelial carcinoma. Cancer Cytopathol. 2018; 126(3): 207–214.